X hits on this document

143 views

0 shares

0 downloads

0 comments

57 / 57

We need adequately powered clinical trials to….

1. Determine what is the most simple, inexpensive, and rapid test of platelet function and/or metabolism genotyping that best predicts clinical outcomes of

antiplatelet therapy for specific patient subgroups?  AND STICK TO IT….results in trials discussed seem to vary by assay!

2. Determine if individual outcomes are affected when treatment is

changed in response to the testing results. i.e. what is our “threshold” or “cutoff” values

3. What the benefit of supplementary treatment with an agent having a different mechanism of action in patients with known hypo-response to a given antiplatelet agent?

4. With emerging agents, is any of this ultimately going to matter?

Adapted from H. Aboul-Enein, Benha Faculty of Medicine

HOW DO WE MOVE FORWARD?

Document info
Document views143
Page views143
Page last viewedMon Dec 05 09:29:24 UTC 2016
Pages57
Paragraphs810
Words3494

Comments